Osteoporosis

Experimental Drugs Offer Promise For Reversing Bone Loss

Published in Women's Health Weekly, March 1st, 1995

Researchers report that alendronate could become one of the first new treatments for osteoporosis in more than a decade.

Alendronate was given to 516 women over three years, producing an average 6.8 percent increase in bone density at the spine, said Merck & Co., which plans next month to submit it for Food and Drug Administration approval.

Patients in the trials in 15 countries outside the United States also showed 4.8 percent and 6.9 percent increases at the two spots on the hip most prone to fracture.

"That's pretty substantial," said Richard Gelula of the National Osteoporosis Foundation in Washington. "If they can reduce...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1995-03-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry